SABA ILAC SANAYIVE
GenericsSABA ILAC SANAYIVE is a generic drug manufacturer focused on Cardiovascular, Ophthalmology.
SABA ILAC SANAYIVE's Key Drugs
SABA ILAC SANAYIVE's core commercial portfolio centers on BRIMONIDINE TARTRATE AND TIMOLOL MALEATE, spanning Cardiovascular and Ophthalmology — its most strategically important drugs approved in the last 15 years.
SABA ILAC SANAYIVE's Recent FDA Approvals
New NDA/BLA approvals for SABA ILAC SANAYIVE over the last two years — novel drugs only, excluding generics and label supplements.
SABA ILAC SANAYIVE's Therapeutic Areas
SABA ILAC SANAYIVE's approved drugs and pipeline span 2 therapeutic areas, led by Cardiovascular and Ophthalmology, across 0 biologic and 0 small-molecule drugs. Weighted by commercial stage — approved drugs count most, then late-stage trials.
SABA ILAC SANAYIVE's Top Competitors
SABA ILAC SANAYIVE's closest competitors by therapeutic-area and drug-target overlap include Novartis, Baxter, and Bayer. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
SABA ILAC SANAYIVE Pipeline Snapshot
Active clinical trials for SABA ILAC SANAYIVE across all therapeutic areas, from ClinicalTrials.gov.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • BRIMONIDINE TARTRATE AND TIMOLOL MALEATE leads revenue
- • Drug-level revenue analysis
Trial Catalysts
- • Cardiovascular pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Revenue forecasts • Trial milestones • Patent risk modeling
Active (1)
Discontinued (0)
Company Info
- First Approval
- 2024-04-02
- Latest
- 2026-07-01
- Applications
- 4